Allgens Medical Technology Co. Ltd. A
Allgens Medical Technology CO., LTD. engages in the research and development, production, and sale of biomedical materials and related medical device products in China. The company offers collagen artificial bone repair materials to agents and terminal hospitals. Its products include Tooth Shell for the treatment of oral or plastic surgery and BonGold for the treatment of orthopedic bone defect r… Read more
Allgens Medical Technology Co. Ltd. A (688613) - Net Assets
Latest net assets as of September 2025: CN¥1.45 Billion CNY
Based on the latest financial reports, Allgens Medical Technology Co. Ltd. A (688613) has net assets worth CN¥1.45 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.54 Billion) and total liabilities (CN¥96.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.45 Billion |
| % of Total Assets | 93.78% |
| Annual Growth Rate | 24.16% |
| 5-Year Change | 117.89% |
| 10-Year Change | N/A |
| Growth Volatility | 30.92 |
Allgens Medical Technology Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Allgens Medical Technology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Allgens Medical Technology Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Allgens Medical Technology Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.42 Billion | +1.16% |
| 2023-12-31 | CN¥1.40 Billion | +5.88% |
| 2022-12-31 | CN¥1.33 Billion | +4.34% |
| 2021-12-31 | CN¥1.27 Billion | +94.97% |
| 2020-12-31 | CN¥651.68 Million | +15.60% |
| 2019-12-31 | CN¥563.76 Million | +24.81% |
| 2018-12-31 | CN¥451.70 Million | +44.68% |
| 2017-12-31 | CN¥312.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Allgens Medical Technology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26679621020.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥254.14 Million | 18.12% |
| Common Stock | CN¥135.55 Million | 9.66% |
| Other Comprehensive Income | CN¥84.15 Million | 6.00% |
| Other Components | CN¥929.04 Million | 66.22% |
| Total Equity | CN¥1.40 Billion | 100.00% |
Allgens Medical Technology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Allgens Medical Technology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cembre S.p.A. Ord
LSE:0DXU
|
$310.46 Million |
|
Shenzhen Rayitek Hi-Tech Film Co. Ltd. A
SHG:688323
|
$310.50 Million |
|
Solid Biosciences LLC
NASDAQ:SLDB
|
$310.51 Million |
|
Flagship Communities Real Estate Investment Trust
PINK:MHCUF
|
$310.53 Million |
|
Luenmei Quantum Co Ltd
SHG:600167
|
$310.32 Million |
|
secunet Security Networks Aktiengesellschaft
F:YSN
|
$310.29 Million |
|
Dermapharm Holding SE
PINK:DMPHF
|
$310.27 Million |
|
MICROVAST HOLD. DL-0001
F:2OZA
|
$310.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allgens Medical Technology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,382,079,651 to 1,402,874,383, a change of 20,794,732 (1.5%).
- Net loss of 12,662,162 reduced equity.
- Dividend payments of 10,778,758 reduced retained earnings.
- Other comprehensive income decreased equity by 13,667,457.
- Other factors increased equity by 57,903,109.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-12.66 Million | -0.9% |
| Dividends Paid | CN¥10.78 Million | -0.77% |
| Other Comprehensive Income | CN¥-13.67 Million | -0.97% |
| Other Changes | CN¥57.90 Million | +4.13% |
| Total Change | CN¥- | 1.50% |
Book Value vs Market Value Analysis
This analysis compares Allgens Medical Technology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.26x to 2.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.85 | CN¥24.08 | x |
| 2018-12-31 | CN¥4.52 | CN¥24.08 | x |
| 2019-12-31 | CN¥4.00 | CN¥24.08 | x |
| 2020-12-31 | CN¥4.67 | CN¥24.08 | x |
| 2021-12-31 | CN¥9.33 | CN¥24.08 | x |
| 2022-12-31 | CN¥9.77 | CN¥24.08 | x |
| 2023-12-31 | CN¥10.45 | CN¥24.08 | x |
| 2024-12-31 | CN¥9.97 | CN¥24.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allgens Medical Technology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.15%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.10x
- Recent ROE (-0.90%) is below the historical average (7.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 7.54% | 25.75% | 0.29x | 1.03x | CN¥-7.69 Million |
| 2018 | 7.52% | 26.67% | 0.24x | 1.20x | CN¥-10.86 Million |
| 2019 | 12.72% | 40.21% | 0.24x | 1.34x | CN¥14.49 Million |
| 2020 | 14.28% | 48.40% | 0.23x | 1.29x | CN¥26.68 Million |
| 2021 | 9.71% | 51.17% | 0.17x | 1.15x | CN¥-3.64 Million |
| 2022 | 7.31% | 38.82% | 0.17x | 1.12x | CN¥-35.08 Million |
| 2023 | 3.92% | 23.95% | 0.15x | 1.10x | CN¥-83.98 Million |
| 2024 | -0.90% | -6.15% | 0.13x | 1.10x | CN¥-152.95 Million |
Industry Comparison
This section compares Allgens Medical Technology Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allgens Medical Technology Co. Ltd. A (688613) | CN¥1.45 Billion | 7.54% | 0.07x | $310.34 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |